sorafenib has been researched along with butyric acid in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (butyric acid) | Trials (butyric acid) | Recent Studies (post-2010) (butyric acid) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 3,556 | 85 | 1,448 |
| Protein | Taxonomy | sorafenib (IC50) | butyric acid (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, Z; Dai, W; Feng, J; Guo, C; Ji, J; Li, J; Li, Y; Wu, J; Wu, L; Xu, X; Yu, Q; Zhang, J; Zheng, Y | 1 |
| Chakraborti, A; Dhiman, RK; Kanthaje, S; Kaur, R; Kumar, M | 1 |
2 other study(ies) available for sorafenib and butyric acid
| Article | Year |
|---|---|
Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c-myc/hexokinase 2 pathway.
Topics: Animals; Butyric Acid; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Proliferation; Glycolysis; Hexokinase; Humans; Lactates; Liver Neoplasms; Mice; Sorafenib | 2022 |
Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Bacteria; Butyric Acid; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; RNA, Ribosomal, 16S; Sorafenib | 2023 |